Ectopic fat and insulin resistance

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 185-191

  Lettner, Angelika ^b   Roden, Michael ^a  

^a HANUSCH HOSPITAL   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

BODY FAT DISTRIBUTION; CALORIC RESTRICTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ECTOPIC FAT; HEART MUSCLE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID OXIDATION; LIPID STORAGE; LIVER PARENCHYMA; MONOTHERAPY; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; SKELETAL MUSCLE; TISSUE SPECIFICITY; ANIMAL; CHORISTOMA; DRUG EFFECT; OBESITY; PATHOLOGY;

ANIMALS; CHORISTOMA; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; PANCREAS; TRIGLYCERIDES;

EID: 52649158262     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0032-z     Document Type: Review

References (51)

1. Krssak M, Roden M: The role of lipid accumulation in liver and muscle for insulin resistance in type 2 diabetes in humans. Rev Endocr Metab Dis 2004, 5:127-135.
2. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463-478.
3. Roden M: Muscle triglycerides and mitochondrial function: possible mechanism for the development of type 2 diabetes. Int J Obes Relat Metab Disord 2005, 29(Suppl 2): S111-S115.
4. Kelley DE, McKolanis TM, Hegazi RA, et al.: Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol 2003, 285: E906-E916.
5. Roden M: Mechanisms of disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006, 2:335-348.
6. Hwang JH, Pan JW, Heydari S, et al.: Regional differences in intramyocellular lipids in humans observed by in vivo 1H-MR spectroscopic imaging. J Appl Pbysiol 2001, 90:1267-1274.
7. Szczepaniak LS, Babcock EE, Schick F, et al.: Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999, 276:E977-E989.
8. Anderwald C, Bernoider E, Krssak M, et al.: Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002, 51:3025-3032.
9. Szczepaniak LS, Dobbins RL, Metzger GJ, et al.: Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49:417-423.
10. Van der Meer RW, Doornbos J, Kozerke S, et al.: Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007, 245:2S1-2S7.
11. Tushuizen ME, Bunck MC, Pouwels PJ, et al.: Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007, 30:2916-2921.
12. Pan DA, Lillioja S, Kriketos AD, et al.: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997, 46:983-988.
13. Phillips DI, Caddy S, Ilic V, et al.: Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996, 45:947-950.
14. Krssak M, Falk Petersen K, Dresner A, et al.: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999, 42:113-116.
15. Jacob S, Machann J, Rett K, et al.: Association of increased intramyocetlular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999, 48:1113-1119.
16. K,autzky-Willer A, Krssak M, Winzer C, et al.: Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes 2003, 52:244-251.
17. Perseghin G, Lattuada G, Danna M, et al.: Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol 2003, 285:E1174-E1181.
18. Sinha R, Dufour S, Petersen KF, et al.: Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002, 51:1022-1027.
19. Goodpaster BH, Thaete FL, Kelley DE: Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000, 71:885-892.
20. Malenfant P, Joanisse DR, Thériault R, et al.: Fat content in individual muscle fibers of lean and obese subjects. Int J Obes Relat Metab Disord 2001, 25:1316-1321.
21. Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001, 86:5755-5761.
22. Thamer C, Machann J, Bachmann O, et al.: Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insullin sensitivity. J Clin Endocrinol Metab 2003, 88:1785-1791.
23. Krssak M, Petersen KF, Bergeron R, et al.: Intramuscular glycogen and intramyocellular lipid utilization during prolonged exercise and recovery in man: a 13C and 1H nuclear magnetic resonance spectroscopy study. J Clin Endocrinol Metab, 2000, 85:748-754.
24. Perseghin G, Scifo P, Danner M, et al.: Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. Am J Physiol 2003, 284:E274-E280.
25. Bachmann OP, Dahl DB, Brechtel K, et al.: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001, 50:2579-2584.
26. Boden G, Lebed B, Schatz M, et al.: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50:1612-1617.
27. Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, et al.: Intramyocellular lipid content and molecular adaptations in response to a 1-week high-fat diet. Obes Res 2005, 13:2088-2094.
28. Stannard SR, Thompson MW, Fairbairn K, et al.: Fasting for 72 h increases intramyocellular lipid content in nondiabetic, physically fit men. Am J Physiol 2002, 283: E1185-E1191.
29. Brehm A, Krssak M, Schmid AI, et al.: Increased lipid availability impairs insutin-stimulated ATP synthesis in human skeletal muscle. Diabetes 2006, 55:136-140.
30. Bruce CR, Anderson MJ, Carey AL, et al.: Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 2003, 88:5444-5451.
31. Petersen KF, Dufour S, Shulman GI.: Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005, 2:e233.
32. Szendroedi J, Schmid AI, Chmelik M, et al.: Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 2007, 4:e154.
33. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al.: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87:3023-3028.
34. Tiikkainen M, Tamminen M, Häkkinen AM, et al.: Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 2002, 10:859-867.
35. Mayerson AB, Hundal RS, Dufour S, et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2000, 51:797-802.
36. Krssak M, Brehm A, Bernroider E, et al.: Postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes, 53:3048-3056.
37. Bisshop PH, de Metz J, Ackermans MT, et al.: Dietary fat content alters insulin-mediated glucose metabolism in healthy men. Am J Clin Nutr 2001, 73:554-559.
38. Samuel VT, Liu ZX, Wang A, et al.: Inhibition of protein kinase C epsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007, 117:739-745.
39. Petersen KF, Dufour S, Savage DB, et al.: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007, 104:12587-12594.
40. Rutter MK, Parise H, Benjamin EJ, et al.: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex related differences in the Framingham Heart Study. Circulation 2003, 107:448-454.
41. Zib I, Jacob AN, Lingvay I, et al.: Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin- treated patients with type 2 diabetes. J Investig Med 2007, 55:230-236.
42. McGavock JM, Lingvay I, Zip I, et al.: Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
43. Frost GS, Goff LM, Hamilton G, et al.: Carbohydrate- induced manipulation of insulin sensitivity independently of intramyocellular lipids. Br J Nutr 2003, 89:365-375.
44. Brechtel K, Niess AM, Machann J, et al.: Utilisation of intramyocellular lipids (IMCLs) during exercise as assessed by proton magnetic resonance spectroscopy (1H-MRS). Horm Metab Res 2001, 33:63-66.
45. Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
46. Carey DG, Cowin GJ, Galloway GJ, et al.: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 2002, 10:1008-1015.
47. Tiikkainen M, Häkkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
48. Teranishi T, Ohara T, Maeda K, et al.: Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007, 56:1418-1424.
49. Brehm A: Comparison of the effects of glimepiride vs. pioglitazone+nateglinide therapy on insulin sensitivity and ectopic fat storage in well-controlled type 2 diabetes. Diabetes 2005, 54(Suppl 1):A381.
50. Juurinen L, Tiikkainen M, Häkkinen AM, et al.: Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol 2007, 292:E829-E835.
51. Juurinen L, Kotronen A, Granér M, et al.: Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab 2008, 93:118-124.